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Abstract
Background: Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a
monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson’s disease
(PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and
dementia. We hypothesized that plasma levels of lipids involved in ceramide metabolism would also be altered in PD non-
GBA mutation carriers and associated with worse cognition.
Methods: Plasma ceramide, monohexosylceramide, and lactosylceramide levels in 26 cognitively normal PD patients, 26 PD
patients with cognitive impairment or dementia, and 5 cognitively normal non-PD controls were determined by LC/ESI/MS/
MS.
Results: Levels of all lipid species were higher in PD patients versus controls. Among PD patients, levels of ceramide C16:0,
C18:0, C20:0, C22:0, and C24:1 and monohexosylceramide C16:0, C20:0 and C24:0 species were higher (all P,0.05)
in those with versus
Conclusion: These results suggest that plasma ceramide and monohexosylceramide metabolism is altered in PD non-GBA
mutation carriers and that higher levels are associated with worse cognition. Additional studies with larger sample sizes,
including cognitively normal controls, are needed to confirm these findings.
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Introduction
The deposition of brain alpha-synuclein, a lipid-binding protein
[1], [2], is the hallmark pathology of the neurodegenerative
process underlying Parkinson’s disease (PD). It has been suggested
that perturbations in ceramide metabolism may contribute to
alpha-synuclein deposition and the formation of Lewy bodies [3].
Indeed, recent evidence suggests that dysregulated ceramide
metabolism may be directly linked to the oligomer formation of
alpha synuclein [4] and also enhance its toxicity [5].
Mutations in the beta-glucosidase gene (GBA) coding for
glucocerebrosidase, which breaks down glucosylceramide into
glucose and ceramide (Figure 1) [6], are the most common genetic
risk factors for sporadic PD, comprising about 7% of all cases [7],
[8]. PD patients who are GBA mutation carriers are more likely to
have an earlier age of onset and to develop cognitive impairment
and dementia [8], [9], [10]. These findings may suggest the critical
role of glucosylceramide and ceramide metabolism in the
development of PD and subsequent cognitive impairment.
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 without cognitive impairment.
To date, little research has examined the role of ceramide
metabolism in PD among non-GBA mutation carriers. Indeed, it is
not known whether ceramide or glucosylceramide levels are
elevated in PD cases or whether higher levels are associated with
cognitive impairment. The point prevalence of PD-Dementia
(PDD) is close to 30% and at least 75% of PD patients who survive
for more than 10 years develop dementia [11]. However, there are
currently no biological or clinical biomarkers to predict those PD
cases that are at greatest risk of developing cognitive impairment.
In the present study, we sought to preliminarily assess whether
plasma levels of lipids involved in ceramide metabolism (cer-
amides, monohexosylceramide, and lactosylceramides) were
altered in non-GBA mutation PD cases with and without cognitive
impairment or dementia.
Patients and Methods
Ethics Statement
The study was approved by the ethics committee of the Medical
Faculty, University of Tuebingen, Germany [12], and was
performed according to the principles expressed in the Declaration
of Helsinki. All participants gave their written informed consent.
Subjects
Participants included 5 cognitively normal (CN) non-PD
patients, 26 cognitively non-affected PD patients (PD-CN), 14
PD-mild cognitive impairment (PD-MCI) patients, and 12 PD-
dementia (PDD) patients recruited from the ward and outpatient
clinic of the Department of Neurodegenerative Diseases, Neurol-
ogy Center of Tuebingen (WM, DB, TG). Eligibility criteria
included a diagnosis of PD based on the UK PD Brain Bank
Criteria [13], age 45–80 years, no prior surgery for PD, no
diagnosis of any other neurological disease, and a MMSE score
$18. Spouses of the patients served as controls. All controls were
determined to be cognitively normal and did not have a
neurological condition.
Blood was collected using standard venipuncture procedures.
GBA mutations in PD patients and controls were determined by
whole gene sequencing; mutation carriers were excluded. PD
patients completed demographic and medical history question-
naires, had a medication inventory, and underwent a compre-
hensive neurological (e.g., Unified Parkinson’s Disease Rating
Scale, Hoehn & Yahr stage), behavioral (e.g., Apathy Evaluation
Scale, short form of the Geriatric Depression Scale) and
neuropsychological assessment (e.g., The Consortium to Establish
a Registry for Alzheimer’s Disease, Trail Making Test, Stroop
Test, Brief Test of Attention, Digit Span forward and backward of
the Wechsler Memory Scale revised) within the scope of the
Dempark/Landscape study as previously described in detail [12].
Diagnostic criteria for PD-MCI followed the Level-1 recom-
mendation of the Movement Disorder Society (MDS) Task Force
Guidelines [14], and for PDD followed the Level-II recommen-
dations [15].
Sphingolipid Assays
A crude lipid extraction of plasma was conducted using a
modified Bligh and Dyer procedure as previously described [16].
Analyses of sphingolipids were performed on a high-performance
liquid chromatography coupled electrospray ionization tandem
mass spectrometer (LC/ESI/MS/MS) (API3000s, Sciex Inc.,
Thornhill, Ontario, Canada) using methods similar to those
previously described [16], [17].
Area under the curve was used to quantitate each sphingolipid
(ceramide, monohexosylceramide, and lactosylceramide) using
MultiQuant (AB Sciex). The resulting data were normalized to
the corresponding internal standard. We examined several
Figure 1. Ceramide and glycolipid metabolism. Products are indicated in bold and italics. Abbreviations for enzymes are as follows: GCase:
glucocerebrosidase; GalCer synthase: galactosylceramide synthase; GluCer synthase: glucosylceramide synthase; GalCeramidase: galactosyl
ceramidase; LacCer synthase: Lactosylceramide synthase; SMase: Sphingomyelinase; SMS: Sphingomyelin synthase.
doi:10.1371/journal.pone.0073094.g001
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carbon-chain lengths of each sphingolipid species, rather than a
sum of each total species, in order to determine whether there
were chain-specific associations. Quantitation was reported as
counts per second (cps). As concentrations were skewed to the
right, similar to previous studies [18], [19], they were log-
transformed prior to analyses.
Statistics
Continuous variables were summarized as median (interquartile
range) and categorical variables as count (percent). Wilcoxon rank
sum tests were used to assess overall group differences. Mann-
Whitney U tests were used to determine differences between all PD
patients and controls, as well as between PD patients with no
cognitive impairment (PD-NC) and PD patients with MCI (PD-
MCI) or dementia (PDD). Spearman correlations assessed the
relationships between the plasma sphingolipids and continuous
variables including age, year of PD onset, Levodopa equivalent
dose, body mass index, and depressive symptoms using the
Geriatric Depression Scale (GDS). Logistic regression was used to
assess the relationship between ceramides, monohexosylceramides
and odds of cognitive impairment among PD patients, controlling
for age, and GDS. All analyses were conducted using STATA
Version 12.1 (StataCorp, College Station, TX).
Results
Characteristics of the participants are shown in Table 1. The
PDD and PD-NC groups were older than controls (Wilcoxon rank
sum test, P=0.009). However, there were no other demographic
or health-related differences by group, including levodopa
equivalence dose. As would be expected, performance on the
PANDA, MMSE, and UPDRS declined with increasing severity
of cognitive impairment (Wilcoxon rank sum test, P=0.0001).
The sphingolipid levels did not correlate with age, age of PD
onset, or Levodopa equivalence dose. They also did not differ by
sex. Only monohexosylceramide C20:0 significantly inversely
correlated with BMI (r =20.417, P=0.0004). Among the PD
patients, several ceramides were positively correlated with
depressive symptoms as measured by the GDS, including C18:0
(r = 0.41, P=0.003), C20:0 (r = 0.356, P=0.009), C22:0
(r = 0.300, P=0.029), C22:1 (r = 0.434, P=0.001), and C26:1
(r = 0.271, P=0.049). Monohexosylceramides C18:0 (r = 0.291,
P=0.035) and C20:0 (r = 0.278, P=0.044) also positively corre-
lated with GDS score.
Compared to controls, PD patients had significantly higher
(P,0.05) levels of nearly all ceramide, monohexosylceramide, and
lactosylceramide species compared to controls (Table 2). We next
determined whether these plasma sphingolipids varied by cogni-
tive status among PD patients. As there were no differences
between the PD-MCI and PDD groups in any lipid (all P.0.20),
we combined these two groups and compared them to the PD-NC
group. The cognitively impaired PD group had significantly higher
levels of ceramide C16:0, C18:0, C20:0, C22:0, and C24:1 and
monohexosylceramide C16:0, C20:0, and C24:0 species (all
P,0.05; Table 2).
In additional analyses among PD patients, we ran logistic
regression models to examine the odds of cognitive impairment
per unit increase in log lipids, controlling for age and depressive
symptoms on the GDS. While the sample size was small,
increasing ceramides C16:0 (OR 7.81, P=0.084), C18:0 (OR
5.56, P=0.035), and C22:0 (OR 2.47, P=0.082) and monohex-
osylceramides C16:0 (OR 3.92, P=0.097), C20:0 (OR 4.43,
P=0.068), C24:0 (OR 2.40, P=0.079) and C16:1 (OR 7.45,
P=0.042) remained significantly or borderline-significantly asso-
ciated with increases odds of being cognitively impaired (e.g.,
having a diagnosis of MCI or dementia).
Table 1. Participant characteristics.
Control (n= 5) PD-NC (n=26) PD-MCI (n =14) PDD (n=12)
Characteristic median (min, max) median (min, max) median (min, max) median (min, max) P value*
Age 67 (50, 75) 70.5 (45, 77) 67.5 (62, 79) 75 (68, 80) .009
Male 3 (60.0%) 18 (69.2%) 11 (78.6%) 9 (75.0%) .863
Education (years) 13.0 (8, 18) 13.0 (8, 17) 11.0 (8, 18) .217
Body mass index 29.4 (27.3, 31.1) 26.8 (20.7, 39.1) 27.7 (21.3, 36.3) 25.0 (19.7, 34.1) .084
Age of PD onset (years) 61.4 (43, 72) 60.3 (42, 73) 62.3 (48, 75) .578
Geriatric Depression Scale 3.0 (0, 13) 3.0 (0, 7) 5.5 (1, 10) .111
Total cholesterol (mg/dl) 144.5 (126.1, 266.0) 160.3 (126.0, 261.9) 156.9 (123.4, 265.2) 162.9 (112.6, 200.7) .988
LDL cholesterol (mg/dl) 72.5 (54.2, 127.5) 86.5 (44.2, 161.1) 83.1 (63.0, 176.5) 95.1 (54.9, 115.3) .875
HDL cholesterol (mg/dl) 53.7 (40.5, 109.9) 45.7 (31.9, 88.3) 42.4 (25.5, 75.0) 47.5 (38.1, 60.8) .398
Triglycerides (mg/dl) 104.4 (76.2, 224.0) 97.6 (53.0, 226.7) 101.4 (40.3, 207.9) 78.3 (60.3, 196.7) .293
Blood glucose (mg/dl) 91.3 (80.2, 147.6) 92.3 (76.7, 116.4) 106.5 (75.7, 236.1) 91.3 (62.5, 210.4) .353
Levodopa equivalent dose (LED) 730 (52, 1960) 895 (205, 1833) 555 (310, 1090) .387
PANDA 22.0 (14, 27) 25.0 (13, 30) 23.5 (11, 27) 10.5 (5, 18) .0001
MMSE 28.0 (28, 29) 29.0 (25, 30) 28.5 (26, 30) 23.5 (20, 26) .0001
UPDRS, part I 2.0 (0, 4) 3.0 (1, 6) 5.0 (3, 11) .0001
UPDRS, part III 1.0 (0, 3) 21.5 (9, 40) 32 (7, 55) 36.5 (16, 48) .0001
PD-NC, Parkinson’s disease-Normal Cognition; PD-MCI, Parkinson’s disease-Mild Cognitive Impairment; PDD, Parkinson’s disease-dementia; LDL, Low density lipoprotein;
HDL, high density lipoprotein; PANDA, Parkinson Neuropsychometric Dementia Assessment; MMSE, Mini-Mental State Examination; UPDRS, Unified Parkinson’s Disease
Rating Scale.
*P-values are based on Wilcoxon rank sum tests to assess overall group differences.
doi:10.1371/journal.pone.0073094.t001
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We also examined other plasma lipids to determine whether the
findings presented above were due to global lipid alterations or
were specific to sphingolipids. Plasma total, LDL, and HDL
cholesterol and triglyceride levels did not significantly differ
between groups or between PD patients and controls (Table 1).
These data suggest that results were specific to ceramides,
monohexosylceramides, and lactosylceramides and are not due
to global lipid effects.
Discussion
In the present study, we determined whether plasma sphingo-
lipids differed in PD patients versus controls and whether these
lipid levels varied by cognitive impairment among PD patients.
Importantly, we found that several species of ceramides, mono-
hexosylceramides, and lactosylceramides were elevated in PD
patients versus controls and were highest among those PD patients
who had cognitive impairment (either MCI or dementia). These
preliminary results suggest the importance of ceramide and
monohexosylceramide metabolism in the pathophysiology of
sporadic PD and could indicate a novel means of identifying
individuals at increased risk of cognitive impairment.
Glucocerebrosidase catalyzes the conversion of glucosylcera-
mide to ceramide and glucose inside lysosomes; lysosomal
processing is the main degradation pathway of alpha-synuclein
[20]. Mutations in the GBA gene coding for glucocerebrosidase
result in a build-up of glucosylceramide (a monohexosylceramide)
within the lysosome and, thus, decrease the degradation of alpha-
synuclein. Notably, a recent study suggested a positive feedforward
loop between increased glucosylceramide and alpha-synuclein
accumulation, leading to neurodegeneration [4]. These experi-
mental results fit with research showing that mutations in
glucocerebrosidase are associated with an increased risk of
sporadic PD, and that these patients have earlier ages of onset
and more cognitive impairment [7], [9]. However, mutations in
glucocerebrosidase, while the most common, only comprise 7% of
all sporadic PD cases. Thus, mechanisms related to the underlying
PD pathology in non-GBA mutation carriers remain to be
identified.
We hypothesized that variations in lipids involved in ceramide
metabolism, including both glucosylceramide and ceramide, might
also be perturbed in persons with PD without specific GBA
mutations, particularly in those with cognitive impairment.
Cellular studies suggest that ceramides may be involved in the
pathogenesis of PD. Dopaminergic neurons positively regulate
neutral sphingomyelinase activity, thereby increasing ceramide
levels, in response to oxidative stress [21]. Post-mortem and in-vitro
Table 2. Group differences in plasma sphingolipids involved in glucosylceramide metabolism.
Plasma
log lipid
Control (n = 5)
median (range)
PD-NC (n=26)
median (range)
PD-MCI (n =14)
median (range)
PDD (n=12)
median (range)
All PD vs. control
P value
PD-NC vs.
PD-MCI/PDD P value
Ceramide
C16:0 11.00 (10.78, 11.24) 11.48 (10.93, 12.26) 11.66 (11.27, 11.95) 11.67 (11.39, 12.79) .0006 .035
C18:0 10.76 (10.43, 11.27) 10.98 (10.24, 12.24) 11.21 (10.44, 11.77) 11.17 (10.93, 12.54) .067 .016
C20:0 11.48 (11.23, 12.40) 12.21 (11.32, 13.58) 12.50 (11.80, 13.27) 12.54 (11.99, 14.10) .006 .037
C22:0 13.00 (12.86, 13.69) 13.63 (12.83, 14.77) 13.95 (12.67, 15.09) 13.90 (13.47, 16.14) .010 .037
C24:0 15.40 (14.69, 15.92) 15.73 (14.37, 16.85) 15.89 (14.17, 17.07) 16.03 (14.55, 18.00) .096 .621
C26:0 11.57 (11.18, 12.19) 11.94 (9.68, 12.84) 12.16 (10.61, 13.51) 12.08 (9.70, 14.07) .096 .510
C22:1 9.21 (9.01, 10.10) 9.86 (8.83, 10.60) 9.97 (9.51, 10.78) 9.91 (9.43, 11.92) .051 .442
C24:1 12.50 (12.49, 13.29) 13.23 (12.34, 14.83) 13.57 (12.67, 14.40) 13.37 (13.22, 15.32) .007 .048
C26:1 9.19 (8.92, 9.59) 9.70 (8.46, 11.05) 9.87 (8.92, 10.74) 9.91 (8.87, 11.77) .024 .380
Monohexylceramides (Glucosylceramides and Galactosylceramides)*
C16:0 11.21 (10.97, 11.67) 11.92 (11.03, 12.79) 12.09 (11.36, 12.78) 12.14 (11.52, 14.29) .001 .046
C18:0 8.62 (8.45, 9.04) 9.11 (8.40, 10.15) 9.20 (8.33, 9.92) 9.15 (8.90, 10.80) .011 .242
C20:0 10.19 (9.90, 10.26) 10.48 (9.79, 11.31) 10.69 (10.07, 11.33) 10.73 (10.10, 12.11) .010 .039
C22:0 13.16 (12.74, 13.36) 13.75 (12.97, 14.61) 13.88 (13.18, 14.68) 14.03 (13.30, 15.52) .001 .148
C24:0 13.64 (13.22, 13.89) 14.17 (13.15, 15.49) 14.56 (13.26, 15.29) 14.53 (13.57, 16.32) .006 .040
C26:0 9.74 (9.37, 10.19) 10.20 (8.82, 11.16) 10.14 (8.41, 11.23) 10.35 (8.17, 12.28) .215 .840
C16:1 9.15 (8.58, 9.50) 9.50 (8.67, 9.99) 9.73 (9.12, 10.34) 9.49 (9.21, 11.72) .011 .089
C22:1 9.41 (9.11, 10.26) 9.94 (9.02, 10.59) 9.96 (9.00, 10.70) 10.02 (9.43, 11.88) .176 .370
C24:1 9.69 (9.30, 13.30) 10.02 (8.48, 11.06) 10.03 (9.26, 11.30) 10.15 (9.27, 12.48) .573 .272
Lactosylceramides
C16:0 13.40 (13.26, 13.51) 13.72 (12.86, 14.59) 13.53 (13.40, 14.17) 13.76 (13.29, 15.16) .006 .164
C18:0 8.75 (8.37, 8.95) 9.03 (8.18, 9.70) 9.24 (8.76, 9.65) 9.24 (8.59, 10.35) .006 .142
C22:0 11.03 (10.35, 11.13) 11.40 (10.84, 12.25) 11.53 (11.13, 12.19) 11.64 (10.89, 12.74) .001 .220
C24:0 10.61 (10.07, 10.76) 10.95 (10.44, 12.14) 11.16 (10.41, 12.05) 11.13 (10.40, 12.54) .009 .621
C24:1 12.10 (11.70, 12.25) 12.57 (11.38, 13.40) 12.72 (12.09, 13.15) 12.71 (11.94, 13.84) .004 .342
PD-NC, Parkinson’s disease-Normal Cognition; PD-MCI, Parkinson’s disease-Mild Cognitive Impairment; PDD, Parkinson’s disease-dementia.
*Glucosylceramides and Galactosylceramides are isomers – this variable includes the total sum of both compounds.
doi:10.1371/journal.pone.0073094.t002
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PD studies have indirectly demonstrated that the activation of
ceramide signaling may mediate the apoptosis observed in the
substantia nigra [22]; decreasing levels of ceramide protect against
MPTP, a specific dopaminergic toxin [23]. Ceramide has also
been shown to induce apoptosis in dopaminergic models [24]; this
effect is neutralized by the non-pathological gene products of
parkin [25] and alpha-synuclein [26]. Both of these proteins have
been implicated in PD and several other neurodegenerative
diseases. However, little research has attempted to translate these
findings to humans. In this study, we did find differences in median
levels of plasma ceramides, monohexosylceramides, and lactosyl-
ceramides by PD status, and by presence of cognitive impairment
among PD cases. Notably, this was not due to a global lipid effect
as there were no differences in cholesterol or triglyceride levels.
Thus, it is likely that the ceramide pathway is significantly altered
in the disease process. We speculate that higher levels of these
lipids may be a marker of more diffuse and severe alpha-synuclein
deposition in the brain, leading to PD with cognitive impairment
or dementia. Thus, it is possible that plasma levels of these lipids
could be promising markers for the identification of different
clinical PD phenotypes and as predictors of disease progression.
Among PD patients, we also found significant positive
correlations between multiple species of ceramides and mono-
hexosylceramides and depressive symptoms, measured by the
GDS. One study of PD patients reported that GBA mutation
carriers had higher depressive symptoms compared to non-carriers
[10], but another study did not find a difference [27]. We have
previously reported elevated plasma ceramide levels in individuals
with a diagnosis of major depression compared to subjects without
[28]. Thus, it is possible that plasma ceramides could be an
indicator or predictor of depression in PD and merits further
investigation.
Limitations of the study warrant consideration. First is the small
sample size, especially of control subjects. While we had highly
significant results despite the small sample size, replication is
needed in larger studies to confirm the findings. Second, the mass
spectrometry method captured monohexosylceramides and did
not isolate glucosylceramides from galactosylceramides. These two
lipids are isomers and require more time and extensive techniques
to separate. As this was the first preliminary examination of these
plasma lipids in PD patients, the more extensive techniques were
not conducted. While we would hypothesize that the finding with
monohexosylceramides is driven by alterations in the levels of
glucosylceramides, and not galactosylceramides, future studies will
need to quantify plasma levels of each lipid.
In conclusion, the present results suggest that plasma ceramide
metabolism is perturbed in PD, and may be particularly important
in the development of cognitive impairment among PD patients.
While larger studies with longitudinal follow-up are needed to
replicate the cross-sectional results and determine the lipids’
predictive value, these preliminary results could indicate a novel
means of identifying individuals at increased risk of PD and those
patients with parkinsonism who are at risk of progressive cognitive
impairment.
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